Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy

Table 2

Treatments and outcomes in previous cases of nivolumab-induced Vogt–Koyanagi–Harada disease-like uveitis.

Authors	Nivolumab	Initial treatment (focal)			Initial treatment (systemic)	Outcome	Second treatment	Outcome
		STTA	Topical steroids	Mydriatics
Current case	Discontinued	Unilateral	+	+	-	Improved, but with hearing loss	PSL 40 mg	Improved hearing loss
Hwang et al. [8]	Discontinued	NR	NR	NR	PSL; 1,000 mg/day	Improved
Minami et al. [9]	Discontinued	Bilateral	+	NR	mPSL; 1,000 mg/day	Improved
Ushio et al. [10]	Discontinued	NR	+	NR	-	Relapse	PSL; 150 mg/day	Improved
Godse et al. [11]	Discontinued	NR	NR	NR	PSL; 1 mg/kg/day	Improved
Ng et al. [12]	Discontinued	-	-	-	-	Worsening	PSL; 60 mg/day	Improved
Czichos et al. [13]	Discontinued	NR	+	+	PSL; 200 mg/day	Improved
Mihailovic et al. [14]	Continued	NR	+	+	PSL; 2 mg/kg/day	Improved, but with macular edema	Intravitreal; triamcinolone; 2 mg	Improved
Gambichler et al. [15]	Discontinued	NR	NR	NR	mPSL; 1,000 mg/day	Improved
Kikuchi et al. [16]	Discontinued	Bilateral	NR	NR	-	No remission	mPSL; 1,000 mg/day	Improved
Obata et al. [17]	Discontinued	NR	+	+	-	Improved
Fujimura et al. [18]	Continued	NR	NR	NR	mPSL; 500 mg/day	Improved
Fujimura et al. [18]	Continued	NR	NR	NR	mPSL; 500 mg/day	Improved
Arai et al. [19]	Continued	NR	+	+	-	Improved
Matsuo et al. [20]	Continued	NR	+	NR	PSL 30 mg	Improved

NR: not reported; STTA: subtenon injection of triamcinolone acetonide; PSL: prednisolone; mPSL: methylprednisolone.